Jodrellin A

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596267

CAS#: 124901-80-0

Description: Jodrellin A is a bioactive chemical.

Chemical Structure

Jodrellin A
CAS# 124901-80-0

Theoretical Analysis

MedKoo Cat#: 596267
Name: Jodrellin A
CAS#: 124901-80-0
Chemical Formula: C24H32O8
Exact Mass: 448.2097
Molecular Weight: 448.51
Elemental Analysis: C, 64.27; H, 7.19; O, 28.54

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Jodrellin A;

IUPAC/Chemical Name: (2R,2'S,4a'R,5'S,7'R,8'R,8a'S,9'R)-7',8'-dimethyl-8'-((2S,3aS,6aR)-2,3,3a,6a-tetrahydrofuro[2,3-b]furan-2-yl)hexahydro-2'H,4'H-spiro[oxirane-2,3'-[2,4a](epoxymethano)naphthalene]-5',9'-diyl diacetate


InChi Code: InChI=1S/C24H32O8/c1-12-7-19(29-13(2)25)24-10-23(11-28-23)18(32-21(24)30-14(3)26)9-16(24)22(12,4)17-8-15-5-6-27-20(15)31-17/h5-6,12,15-21H,7-11H2,1-4H3/t12-,15-,16+,17+,18+,19+,20-,21+,22-,23-,24-/m1/s1

SMILES Code: CC(O[C@H]1C[C@@H](C)[C@]([C@@H]2C[C@@H]3[C@H](OC=C3)O2)(C)[C@H]4[C@@]1(C[C@]56OC6)[C@@H](OC(C)=O)O[C@H]5C4)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 448.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Koh SB, Wallez Y, Dunlop CR, Bernaldo de Quirós Fernández S, Bapiro TE, Richards FM, Jodrell DI. Mechanistic distinctions between CHK1 and WEE1 inhibition guide the scheduling of triple therapy with gemcitabine. Cancer Res. 2018 May 7. pii: canres.3932.2017. doi: 10.1158/0008-5472.CAN-17-3932. [Epub ahead of print] PubMed PMID: 29735549.

2: Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ. CSF1R(+) Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype. Cell Rep. 2018 May 1;23(5):1448-1460. doi: 10.1016/j.celrep.2018.03.131. PubMed PMID: 29719257; PubMed Central PMCID: PMC5946718.

3: Fornari C, O'Connor LO, Yates JWT, Cheung SYA, Jodrell DI, Mettetal JT, Collins TA. Understanding Hematological Toxicities Using Mathematical Modeling. Clin Pharmacol Ther. 2018 Mar 31. doi: 10.1002/cpt.1080. [Epub ahead of print] Review. PubMed PMID: 29604045.

4: Sng CCT, O'Byrne S, Prigozhin DM, Bauer MR, Harvey JC, Ruhle M, Challis BG, Lear S, Roberts LD, Workman S, Janowitz T, Magiera L, Doffinger R, Buckland MS, Jodrell DJ, Semple RK, Wilson TJ, Modis Y, Thaventhiran JED. A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway. J Allergy Clin Immunol. 2018 Mar 6. pii: S0091-6749(18)30327-0. doi: 10.1016/j.jaci.2018.01.048. [Epub ahead of print] PubMed PMID: 29522842.

5: Cook N, Basu B, Smith DM, Gopinathan A, Evans J, Steward WP, Palmer D, Propper D, Venugopal B, Hategan M, Anthoney DA, Hampson LV, Nebozhyn M, Tuveson D, Farmer-Hall H, Turner H, McLeod R, Halford S, Jodrell D. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer. 2018 Mar 20;118(6):793-801. doi: 10.1038/bjc.2017.495. Epub 2018 Feb 13. PubMed PMID: 29438372; PubMed Central PMCID: PMC5877439.

6: Connell CM, Raby SEM, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T. Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist. 2018 Jan;23(1):116-117. doi: 10.1634/theoncologist.2017-0226. Epub 2017 Oct 11. PubMed PMID: 29021379; PubMed Central PMCID: PMC5759814.

7: Janowitz T, Williams EH, Marshall A, Ainsworth N, Thomas PB, Sammut SJ, Shepherd S, White J, Mark PB, Lynch AG, Jodrell DI, Tavaré S, Earl H. New Model for Estimating Glomerular Filtration Rate in Patients With Cancer. J Clin Oncol. 2017 Aug 20;35(24):2798-2805. doi: 10.1200/JCO.2017.72.7578. Epub 2017 Jul 7. PubMed PMID: 28686534; PubMed Central PMCID: PMC5562175.

8: Jackson RC, Di Veroli GY, Koh SB, Goldlust I, Richards FM, Jodrell DI. Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy. PLoS Comput Biol. 2017 May 3;13(5):e1005529. doi: 10.1371/journal.pcbi.1005529. eCollection 2017 May. PubMed PMID: 28467408; PubMed Central PMCID: PMC5435348.

9: Connell CM, Raby S, Beh I, Flint TR, Williams EH, Fearon DT, Jodrell DI, Janowitz T. Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes. Ann Oncol. 2017 Jul 1;28(7):1678-1679. doi: 10.1093/annonc/mdx181. PubMed PMID: 28430855; PubMed Central PMCID: PMC5834107.

10: Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, Jodrell DI, Verbeke C, Li X, Heuchel R, Löhr JM, Johnsen SA, Gress TM, Ellenrieder V, Neesse A. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut. 2018 Mar;67(3):497-507. doi: 10.1136/gutjnl-2016-311954. Epub 2017 Jan 10. PubMed PMID: 28077438; PubMed Central PMCID: PMC5868285.

11: Koh SB, Mascalchi P, Rodriguez E, Lin Y, Jodrell DI, Richards FM, Lyons SK. A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level. J Cell Sci. 2017 Jan 15;130(2):512-520. doi: 10.1242/jcs.195164. Epub 2016 Nov 25. PubMed PMID: 27888217.

12: Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT. Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metab. 2016 Nov 8;24(5):672-684. doi: 10.1016/j.cmet.2016.10.010. PubMed PMID: 27829137; PubMed Central PMCID: PMC5106372.

13: Driscoll DR, Karim SA, Sano M, Gay DM, Jacob W, Yu J, Mizukami Y, Gopinathan A, Jodrell DI, Evans TR, Bardeesy N, Hall MN, Quattrochi BJ, Klimstra DS, Barry ST, Sansom OJ, Lewis BC, Morton JP. mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer. Cancer Res. 2016 Dec 1;76(23):6911-6923. Epub 2016 Oct 6. PubMed PMID: 27758884; PubMed Central PMCID: PMC5135633.

14: Bapiro TE, Richards FM, Jodrell DI. Understanding the Complexity of Porous Graphitic Carbon (PGC) Chromatography: Modulation of Mobile-Stationary Phase Interactions Overcomes Loss of Retention and Reduces Variability. Anal Chem. 2016 Jun 21;88(12):6190-4. doi: 10.1021/acs.analchem.6b01167. Epub 2016 Jun 8. PubMed PMID: 27228284; PubMed Central PMCID: PMC5362737.

15: Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, Jodrell DI. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016 Sep 15;32(18):2866-8. doi: 10.1093/bioinformatics/btw230. Epub 2016 Apr 25. PubMed PMID: 27153664; PubMed Central PMCID: PMC5018366.

16: McCann KJ, Mander A, Cazaly A, Chudley L, Stasakova J, Thirdborough S, King A, Lloyd-Evans P, Buxton E, Edwards C, Halford S, Bateman A, O'Callaghan A, Clive S, Anthoney A, Jodrell DI, Weinschenk T, Simon P, Sahin U, Thomas GJ, Stevenson FK, Ottensmeier CH. Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. Clin Cancer Res. 2016 Oct 1;22(19):4827-4836. doi: 10.1158/1078-0432.CCR-15-2507. Epub 2016 Apr 18. PubMed PMID: 27091407; PubMed Central PMCID: PMC5330406.

17: Wörmann SM, Song L, Ai J, Diakopoulos KN, Kurkowski MU, Görgülü K, Ruess D, Campbell A, Doglioni C, Jodrell D, Neesse A, Demir IE, Karpathaki AP, Barenboim M, Hagemann T, Rose-John S, Sansom O, Schmid RM, Protti MP, Lesina M, Algül H. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival. Gastroenterology. 2016 Jul;151(1):180-193.e12. doi: 10.1053/j.gastro.2016.03.010. Epub 2016 Mar 19. PubMed PMID: 27003603.

18: Gopinathan A, Morton JP, Jodrell DI, Sansom OJ. GEMMs as preclinical models for testing pancreatic cancer therapies. Dis Model Mech. 2015 Oct 1;8(10):1185-200. doi: 10.1242/dmm.021055. Review. PubMed PMID: 26438692; PubMed Central PMCID: PMC4610236.

19: Di Veroli GY, Fornari C, Goldlust I, Mills G, Koh SB, Bramhall JL, Richards FM, Jodrell DI. An automated fitting procedure and software for dose-response curves with multiphasic features. Sci Rep. 2015 Oct 1;5:14701. doi: 10.1038/srep14701. PubMed PMID: 26424192; PubMed Central PMCID: PMC4589737.

20: Koh SB, Courtin A, Boyce RJ, Boyle RG, Richards FM, Jodrell DI. CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus. Cancer Res. 2015 Sep 1;75(17):3583-95. doi: 10.1158/0008-5472.CAN-14-3347. Epub 2015 Jul 3. PubMed PMID: 26141863.